Literature DB >> 27463679

Latency reversal and viral clearance to cure HIV-1.

David M Margolis1, J Victor Garcia2, Daria J Hazuda3, Barton F Haynes4.   

Abstract

Research toward a cure for human immunodeficiency virus type 1 (HIV-1) infection has joined prevention and treatment efforts in the global public health agenda. A major approach to HIV eradication envisions antiretroviral suppression, paired with targeted therapies to enforce the expression of viral antigen from quiescent HIV-1 genomes, and immunotherapies to clear latent infection. These strategies are targeted to lead to viral eradication--a cure for AIDS. Paired testing of latency reversal and clearance strategies has begun, but additional obstacles to HIV eradication may emerge. Nevertheless, there is reason for optimism that advances in long-acting antiretroviral therapy and HIV prevention strategies will contribute to efforts in HIV cure research and that the implementation of these efforts will synergize to markedly blunt the effect of the HIV pandemic on society.
Copyright © 2016, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27463679      PMCID: PMC5021637          DOI: 10.1126/science.aaf6517

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  108 in total

1.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

Authors:  Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano
Journal:  Nat Med       Date:  2003-05-18       Impact factor: 53.440

2.  Repression of human immunodeficiency virus type 1 through the novel cooperation of human factors YY1 and LSF.

Authors:  F Romerio; M N Gabriel; D M Margolis
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

3.  Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.

Authors:  Josep M Llibre; Maria J Buzón; Marta Massanella; Anna Esteve; Viktor Dahl; Maria C Puertas; Pere Domingo; Josep M Gatell; Maria Larrouse; Mar Gutierrez; Sarah Palmer; Mario Stevenson; Julià Blanco; Javier Martinez-Picado; Bonaventura Clotet
Journal:  Antivir Ther       Date:  2011-09-28

4.  HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

Authors:  Maria J Buzón; Marta Massanella; Josep M Llibre; Anna Esteve; Viktor Dahl; Maria C Puertas; Josep M Gatell; Pere Domingo; Roger Paredes; Mark Sharkey; Sarah Palmer; Mario Stevenson; Bonaventura Clotet; Julià Blanco; Javier Martinez-Picado
Journal:  Nat Med       Date:  2010-03-14       Impact factor: 53.440

5.  Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire.

Authors:  Joseph P Casazza; Kathryn A Bowman; Selorm Adzaku; Emily C Smith; Mary E Enama; Robert T Bailer; David A Price; Emma Gostick; Ingelise J Gordon; David R Ambrozak; Martha C Nason; Mario Roederer; Charla A Andrews; Frank M Maldarelli; Ann Wiegand; Mary F Kearney; Deborah Persaud; Carrie Ziemniak; Raphael Gottardo; Julie E Ledgerwood; Barney S Graham; Richard A Koup
Journal:  J Infect Dis       Date:  2013-03-12       Impact factor: 5.226

6.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

Review 7.  In vivo platforms for analysis of HIV persistence and eradication.

Authors:  J Victor Garcia
Journal:  J Clin Invest       Date:  2016-02-01       Impact factor: 14.808

8.  Generation of HIV latency in humanized BLT mice.

Authors:  Paul W Denton; Rikke Olesen; Shailesh K Choudhary; Nancy M Archin; Angela Wahl; Michael D Swanson; Morgan Chateau; Tomonori Nochi; John F Krisko; Rae Ann Spagnuolo; David M Margolis; J Victor Garcia
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

9.  Immune clearance of highly pathogenic SIV infection.

Authors:  Scott G Hansen; Michael Piatak; Abigail B Ventura; Colette M Hughes; Roxanne M Gilbride; Julia C Ford; Kelli Oswald; Rebecca Shoemaker; Yuan Li; Matthew S Lewis; Awbrey N Gilliam; Guangwu Xu; Nathan Whizin; Benjamin J Burwitz; Shannon L Planer; John M Turner; Alfred W Legasse; Michael K Axthelm; Jay A Nelson; Klaus Früh; Jonah B Sacha; Jacob D Estes; Brandon F Keele; Paul T Edlefsen; Jeffrey D Lifson; Louis J Picker
Journal:  Nature       Date:  2013-09-11       Impact factor: 49.962

10.  Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient.

Authors:  Steven A Yukl; Eli Boritz; Michael Busch; Christopher Bentsen; Tae-Wook Chun; Daniel Douek; Evelyn Eisele; Ashley Haase; Ya-Chi Ho; Gero Hütter; J Shawn Justement; Sheila Keating; Tzong-Hae Lee; Peilin Li; Danielle Murray; Sarah Palmer; Christopher Pilcher; Satish Pillai; Richard W Price; Meghan Rothenberger; Timothy Schacker; Janet Siliciano; Robert Siliciano; Elizabeth Sinclair; Matt Strain; Joseph Wong; Douglas Richman; Steven G Deeks
Journal:  PLoS Pathog       Date:  2013-05-09       Impact factor: 6.823

View more
  126 in total

1.  Structural mechanism for HIV-1 TAR loop recognition by Tat and the super elongation complex.

Authors:  Ursula Schulze-Gahmen; James H Hurley
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-04       Impact factor: 11.205

2.  The Activation State of CD4 T Cells Alters Cellular Peptidase Activities, HIV Antigen Processing, and MHC Class I Presentation in a Sequence-Dependent Manner.

Authors:  Julie Boucau; Julien Madouasse; Georgio Kourjian; Christopher S Carlin; Daniel Wambua; Matthew J Berberich; Sylvie Le Gall
Journal:  J Immunol       Date:  2019-04-01       Impact factor: 5.422

3.  Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.

Authors:  Nancie M Archin; Jennifer L Kirchherr; Julia Am Sung; Genevieve Clutton; Katherine Sholtis; Yinyan Xu; Brigitte Allard; Erin Stuelke; Angela D Kashuba; Joann D Kuruc; Joseph Eron; Cynthia L Gay; Nilu Goonetilleke; David M Margolis
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

4.  Pharmacokinetic stability of macrocyclic peptide triazole HIV-1 inactivators alone and in liposomes.

Authors:  Rachna Aneja; Antonella Grigoletto; Aakansha Nangarlia; Adel A Rashad; Steven Wrenn; Jeffrey M Jacobson; Gianfranco Pasut; Irwin Chaiken
Journal:  J Pept Sci       Date:  2019-02-27       Impact factor: 1.905

5.  SAMHD1 Impairs HIV-1 Gene Expression and Negatively Modulates Reactivation of Viral Latency in CD4+ T Cells.

Authors:  Jenna M Antonucci; Sun Hee Kim; Corine St Gelais; Serena Bonifati; Tai-Wei Li; Olga Buzovetsky; Kirsten M Knecht; Alice A Duchon; Yong Xiong; Karin Musier-Forsyth; Li Wu
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

6.  Control of the HIV-1 DNA Reservoir Is Associated In Vivo and In Vitro with NKp46/NKp30 (CD335 CD337) Inducibility and Interferon Gamma Production by Transcriptionally Unique NK Cells.

Authors:  Francesco Marras; Anna Casabianca; Federica Bozzano; Maria Libera Ascierto; Chiara Orlandi; Antonio Di Biagio; Emanuele Pontali; Chiara Dentone; Giancarlo Orofino; Laura Nicolini; Lucia Taramasso; Mauro Magnani; Francesco M Marincola; Ena Wang; Lorenzo Moretta; Andrea De Maria
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

7.  A New Agent in the Strategy to Cure AIDS.

Authors:  John A Zaia
Journal:  Mol Ther       Date:  2016-11       Impact factor: 11.454

8.  Short-Term Pegylated Interferon α2a Treatment Does Not Significantly Reduce the Viral Reservoir of Simian Immunodeficiency Virus-Infected, Antiretroviral Therapy-Treated Rhesus Macaques.

Authors:  David Palesch; Steven E Bosinger; Maud Mavigner; James M Billingsley; Cameron Mattingly; Diane G Carnathan; Mirko Paiardini; Ann Chahroudi; Thomas H Vanderford; Guido Silvestri
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

Review 9.  Bispecific antibodies: Potential immunotherapies for HIV treatment.

Authors:  Giulia Fabozzi; Amarendra Pegu; Richard A Koup; Constantinos Petrovas
Journal:  Methods       Date:  2018-10-22       Impact factor: 3.608

10.  Cyclin-dependent kinase 7 (CDK7)-mediated phosphorylation of the CDK9 activation loop promotes P-TEFb assembly with Tat and proviral HIV reactivation.

Authors:  Uri Mbonye; Benlian Wang; Giridharan Gokulrangan; Wuxian Shi; Sichun Yang; Jonathan Karn
Journal:  J Biol Chem       Date:  2018-05-09       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.